Meta-analysis of prostate cancer gene expression data identifies a novel discriminatory signature enriched for glycosylating enzymes

详细信息    查看全文

• 作者：Stefan J Barfeld (2)
  Philip East (1)
  Verena Zuber (2)
  Ian G Mills (2) (3)
  
  2. Prostate Cancer Research Group ; 鈥塁entre for Molecular Medicine Norway (NCMM) ; Nordic EMBL Partnership University of Oslo and Oslo University Hospital ; Oslo ; Norway
  1. Bioinformatics & Biostatistics ; Cancer Research UK London Research Institute ; 44 Lincoln鈥檚 Inn Fields ; London ; WC2A 3PX ; UK
  3. Department of Cancer Prevention and Urology ; Institute of Cancer Research and Oslo University Hospital ; Oslo ; Norway
  
• 关键词：Transcription ; Prostate cancer ; Signature
• 刊名：BMC Medical Genomics
• 出版年：2014
• 出版时间：December 2014
• 年：2014
• 卷：7
• 期：1
• 全文大小：4,127 KB
• 参考文献：1. Rhodes, DR, Yu, J, Shanker, K, Deshpande, N, Varambally, R, Ghosh, D, Barrette, T, Pandey, A, Chinnaiyan, AM (2004) Large-scale meta-analysis of cancer microarray data identifies common transcriptional profiles of neoplastic transformation and progression. Proc Natl Acad Sci U S A 101: pp. 9309-9314 CrossRef
  2. Segal, E, Friedman, N, Koller, D, Regev, A (2004) A module map showing conditional activity of expression modules in cancer. Nat Genet 36: pp. 1090-1098 CrossRef
  3. Horvath, S, Zhang, B, Carlson, M, Lu, KV, Zhu, S, Felciano, RM, Laurance, MF, Zhao, W, Qi, S, Chen, Z, Lee, Y, Scheck, AC, Liau, LM, Wu, H, Geschwind, DH, Febbo, PG, Kornblum, HI, Cloughesy, TF, Nelson, SF, Mischel, PS (2006) Analysis of oncogenic signaling networks in glioblastoma identifies ASPM as a molecular target. Proc Natl Acad Sci U S A 103: pp. 17402-17407 CrossRef
  4. Stuart, RO, Wachsman, W, Berry, CC, Wang-Rodriguez, J, Wasserman, L, Klacansky, I, Masys, D, Arden, K, Goodison, S, McClelland, M, Wang, Y, Sawyers, A, Kalcheva, I, Tarin, D, Mercola, D (2004) In silico dissection of cell-type-associated patterns of gene expression in prostate cancer. Proc Natl Acad Sci USA 101: pp. 615-620 2536479100" target="_blank" title="It opens in new window">CrossRef
  5. Tomlins, SA, Mehra, R, Rhodes, DR, Cao, X, Wang, L, Dhanasekaran, SM, Kalyana-Sundaram, S, Wei, JT, Rubin, MA, Pienta, KJ, Shah, RB, Chinnaiyan, AM (2007) Integrative molecular concept modeling of prostate cancer progression. Nat Genet 39: pp. 41-51 CrossRef
  6. Ramaswamy, S, Ross, KN, Lander, ES, Golub, TR (2003) A molecular signature of metastasis in primary solid tumors. Nat Genet 33: pp. 49-54 CrossRef
  7. Hoerl, AE, Kennard, RW (1970) Ridge regression: biased estimation for nonorthogonal problems. Technometrics 12: pp. 55-67 CrossRef
  8. Varambally, S, Yu, J, Laxman, B, Rhodes, DR, Mehra, R, Tomlins, SA, Shah, RB, Chandran, U, Monzon, FA, Becich, MJ, Wei, JT, Pienta, KJ, Ghosh, D, Rubin, MA, Chinnaiyan, AM (2005) Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. Cancer Cell 8: pp. 393-406 2005.10.001" target="_blank" title="It opens in new window">CrossRef
  9. Ward, JH (1963) Hierarchical grouping to optimize an objective function. J Am Stat Assoc 58: pp. 236-244 21459.1963.10500845" target="_blank" title="It opens in new window">CrossRef
  10. McQuitty, LL (1966) Similarity analysis by reciprocal pairs for discrete and continuous data. Educ Psychol Measure 26: pp. 825-831 2600402" target="_blank" title="It opens in new window">CrossRef
  11. Shannon, CE (1948) A mathematical theory of communication. Bell Syst Tech J 27: pp. 379-423 2/j.1538-7305.1948.tb01338.x" target="_blank" title="It opens in new window">CrossRef
  12. Chen, B-S, Li, C-W (2010) On the interplay between entropy and robustness of gene regulatory networks. Entropy 12: pp. 1071-1101 2051071" target="_blank" title="It opens in new window">CrossRef
  13. Furlanello, C, Serafini, M, Merler, S, Jurman, G (2003) Entropy-based gene ranking without selection bias for the predictive classification of microarray data. BMC Bioinformatics 4: pp. 54 2105-4-54" target="_blank" title="It opens in new window">CrossRef
  14. Cuzick, J, Swanson, GP, Fisher, G, Brothman, AR, Berney, DM, Reid, JE, Mesher, D, Speights, VO, Stankiewicz, E, Foster, CS, Moller, H, Scardino, P, Warren, JD, Park, J, Younus, A, Flake, DD, Wagner, S, Gutin, A, Lanchbury, JS, Stone, S, Transatlantic Prostate, G (2011) Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study. Lancet Oncol 12: pp. 245-255 2045(10)70295-3" target="_blank" title="It opens in new window">CrossRef
  15. Fukuma, Y, Matsui, H, Koike, H, Sekine, Y, Shechter, I, Ohtake, N, Nakata, S, Ito, K, Suzuki, K (2012) Role of squalene synthase in prostate cancer risk and the biological aggressiveness of human prostate cancer. Prostate Cancer Prostatic Dis 15: pp. 339-345 2012.14" target="_blank" title="It opens in new window">CrossRef
  16. Cuzick, J, Berney, DM, Fisher, G, Mesher, D, Moller, H, Reid, JE, Perry, M, Park, J, Younus, A, Gutin, A, Foster, CS, Scardino, P, Lanchbury, JS, Stone, S (2012) Prognostic value of a cell cycle progression signature for prostate cancer death in a conservatively managed needle biopsy cohort. Br J Cancer 106: pp. 1095-1099 2012.39" target="_blank" title="It opens in new window">CrossRef
  17. Yuan, X, Cai, C, Chen, S, Yu, Z, Balk, SP (2014) Androgen receptor functions in castration-resistant prostate cancer and mechanisms of resistance to new agents targeting the androgen axis. Oncogene 33: pp. 2815-2825 2013.235" target="_blank" title="It opens in new window">CrossRef
  18. Jenkins, RB, Qian, J, Lieber, MM, Bostwick, DG (1997) Detection of c-myc oncogene amplification and chromosomal anomalies in metastatic prostatic carcinoma by fluorescence in situ hybridization. Cancer Res 57: pp. 524-531
  19. Ellwood-Yen, K, Graeber, TG, Wongvipat, J, Iruela-Arispe, ML, Zhang, J, Matusik, R, Thomas, GV, Sawyers, CL (2003) Myc-driven murine prostate cancer shares molecular features with human prostate tumors. Cancer Cell 4: pp. 223-238 CrossRef
  20. Mikaelsson, E, Danesh-Manesh, AH, Luppert, A, Jeddi-Tehrani, M, Rezvany, MR, Sharifian, RA, Safaie, R, Roohi, A, Osterborg, A, Shokri, F, Mellstedt, H, Rabbani, H (2005) Fibromodulin, an extracellular matrix protein: characterization of its unique gene and protein expression in B-cell chronic lymphocytic leukemia and mantle cell lymphoma. Blood 105: pp. 4828-4835 2/blood-2004-10-3941" target="_blank" title="It opens in new window">CrossRef
  21. Vallat, L, Magdelenat, H, Merle-Beral, H, Masdehors, P, Potocki De Montalk, G, Davi, F, Kruhoffer, M, Sabatier, L, Orntoft, TF, Delic, J (2003) The resistance of B-CLL cells to DNA damage-induced apoptosis defined by DNA microarrays. Blood 101: pp. 4598-4606 2/blood-2002-06-1743" target="_blank" title="It opens in new window">CrossRef
  22. Levens, E, Luo, X, Ding, L, Williams, RS, Chegini, N (2005) Fibromodulin is expressed in leiomyoma and myometrium and regulated by gonadotropin-releasing hormone analogue therapy and TGF-beta through Smad and MAPK-mediated signalling. Mol Hum Reprod 11: pp. 489-494 CrossRef
  23. Vizio, D, Morello, M, Sotgia, F, Pestell, RG, Freeman, MR, Lisanti, MP (2009) An absence of stromal caveolin-1 is associated with advanced prostate cancer, metastatic disease and epithelial Akt activation. Cell Cycle 8: pp. 2420-2424 CrossRef
  24. Taylor, BS, Schultz, N, Hieronymus, H, Gopalan, A, Xiao, Y, Carver, BS, Arora, VK, Kaushik, P, Cerami, E, Reva, B, Antipin, Y, Mitsiades, N, Landers, T, Dolgalev, I, Major, JE, Wilson, M, Socci, ND, Lash, AE, Heguy, A, Eastham, JA, Scher, HI, Reuter, VE, Scardino, PT, Sander, C, Sawyers, CL, Gerald, WL (2010) Integrative genomic profiling of human prostate cancer. Cancer Cell 18: pp. 11-22 2010.05.026" target="_blank" title="It opens in new window">CrossRef
  25. Rhodes, DR, Yu, J, Shanker, K, Deshpande, N, Varambally, R, Ghosh, D, Barrette, T, Pandey, A, Chinnaiyan, AM (2004) ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia 6: pp. 1-6 2" target="_blank" title="It opens in new window">CrossRef
  26. Itkonen HM, Engedal N, Babaie E, Luhr M, Guldvik IJ, Minner S, Hohloch J, Tsourlakis MC, Schlomm T, Mills IG: UAP1 is overexpressed in prostate cancer and is protective against inhibitors of N-linked glycosylation. / Oncogene 2014. Advance online publication 22nd September; doi: 10.1038/onc.2014.307
  27. Hagisawa, S, Ohyama, C, Takahashi, T, Endoh, M, Moriya, T, Nakayama, J, Arai, Y, Fukuda, M (2005) Expression of core 2 beta1,6-N-acetylglucosaminyltransferase facilitates prostate cancer progression. Glycobiology 15: pp. 1016-1024 CrossRef
  28. Ma, W, Diep, K, Fritsche, HA, Shore, N, Albitar, M (2014) Diagnostic and prognostic scoring system for prostate cancer using urine and plasma biomarkers. Genet Test Mol Biomarkers 18: pp. 156-163 2013.0424" target="_blank" title="It opens in new window">CrossRef
  29. Kamigaito, T, Okaneya, T, Kawakubo, M, Shimojo, H, Nishizawa, O, Nakayama, J (2014) Overexpression of O-GlcNAc by prostate cancer cells is significantly associated with poor prognosis of patients. Prostate Cancer Prostatic Dis 17: pp. 18-22 2013.56" target="_blank" title="It opens in new window">CrossRef
  30. Itkonen, HM, Minner, S, Guldvik, IJ, Sandmann, MJ, Tsourlakis, MC, Berge, V, Svindland, A, Schlomm, T, Mills, IG (2013) O-GlcNAc transferase integrates metabolic pathways to regulate the stability of c-MYC in human prostate cancer cells. Cancer Res 73: pp. 5277-5287 2.CAN-13-0549" target="_blank" title="It opens in new window">CrossRef
  31. Gurel, B, Iwata, T, Koh, CM, Jenkins, RB, Lan, F, Dang, C, Hicks, JL, Morgan, J, Cornish, TC, Sutcliffe, S, Isaacs, WB, Luo, J, Marzo, AM (2008) Nuclear MYC protein overexpression is an early alteration in human prostate carcinogenesis. Mod Pathol 21: pp. 1156-1167 2008.111" target="_blank" title="It opens in new window">CrossRef
  32. Chou, TY, Hart, GW, Dang, CV (1995) c-Myc is glycosylated at threonine 58, a known phosphorylation site and a mutational hot spot in lymphomas. J Biol Chem 270: pp. 18961-18965 270.43.25935" target="_blank" title="It opens in new window">CrossRef
  33. Tomlins, SA, Rhodes, DR, Perner, S, Dhanasekaran, SM, Mehra, R, Sun, XW, Varambally, S, Cao, X, Tchinda, J, Kuefer, R, Lee, C, Montie, JE, Shah, RB, Pienta, KJ, Rubin, MA, Chinnaiyan, AM (2005) Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310: pp. 644-648 26/science.1117679" target="_blank" title="It opens in new window">CrossRef
  34. Deyoung, MP, Scheurle, D, Damania, H, Zylberberg, C, Narayanan, R (2002) Down鈥檚 syndrome-associated single minded gene as a novel tumor marker. Anticancer Res 22: pp. 3149-3157
  35. Halvorsen, OJ, Rostad, K, Oyan, AM, Puntervoll, H, Bo, TH, Stordrange, L, Olsen, S, Haukaas, SA, Hood, L, Jonassen, I, Kalland, KH, Akslen, LA (2007) Increased expression of SIM2-s protein is a novel marker of aggressive prostate cancer. Clin Cancer Res 13: pp. 892-897 2.CCR-06-1207" target="_blank" title="It opens in new window">CrossRef
  36. Koh, CM, Gurel, B, Sutcliffe, S, Aryee, MJ, Schultz, D, Iwata, T, Uemura, M, Zeller, KI, Anele, U, Zheng, Q, Hicks, JL, Nelson, WG, Dang, CV, Yegnasubramanian, S, Marzo, AM (2011) Alterations in nucleolar structure and gene expression programs in prostatic neoplasia are driven by the MYC oncogene. Am J Pathol 178: pp. 1824-1834 2010.12.040" target="_blank" title="It opens in new window">CrossRef
  37. Wang, L, Li, Y, Yang, X, Yuan, H, Li, X, Qi, M, Chang, YW, Wang, C, Fu, W, Yang, M, Zhang, J, Han, B (2014) ERG-SOX4 interaction promotes epithelial-mesenchymal transition in prostate cancer cells. Prostate 74: pp. 647-658 2/pros.22783" target="_blank" title="It opens in new window">CrossRef
  38. Leshem, O, Madar, S, Kogan-Sakin, I, Kamer, I, Goldstein, I, Brosh, R, Cohen, Y, Jacob-Hirsch, J, Ehrlich, M, Ben-Sasson, S, Goldfinger, N, Loewenthal, R, Gazit, E, Rotter, V, Berger, R (2011) TMPRSS2/ERG promotes epithelial to mesenchymal transition through the ZEB1/ZEB2 axis in a prostate cancer model. PLoS One 6: pp. e21650 21650" target="_blank" title="It opens in new window">CrossRef
  39. Ribeiro, FR, Paulo, P, Costa, VL, Barros-Silva, JD, Ramalho-Carvalho, J, Jeronimo, C, Henrique, R, Lind, GE, Skotheim, RI, Lothe, RA, Teixeira, MR (2011) Cysteine-rich secretory protein-3 (CRISP3) is strongly up-regulated in prostate carcinomas with the TMPRSS2-ERG fusion gene. PLoS One 6: pp. e22317 22317" target="_blank" title="It opens in new window">CrossRef
  40. Itkonen, HM, Mills, IG (2013) N-linked glycosylation supports cross-talk between receptor tyrosine kinases and androgen receptor. PLoS One 8: pp. e65016 CrossRef
  41. Visakorpi, T, Hyytinen, E, Koivisto, P, Tanner, M, Keinanen, R, Palmberg, C, Palotie, A, Tammela, T, Isola, J, Kallioniemi, OP (1995) In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet 9: pp. 401-406 CrossRef
  42. Tomlins, SA, Aubin, SM, Siddiqui, J, Lonigro, RJ, Sefton-Miller, L, Miick, S, Williamsen, S, Hodge, P, Meinke, J, Blase, A, Penabella, Y, Day, JR, Varambally, R, Han, B, Wood, D, Wang, L, Sanda, MG, Rubin, MA, Rhodes, DR, Hollenbeck, B, Sakamoto, K, Silberstein, JL, Fradet, Y, Amberson, JB, Meyers, S, Palanisamy, N, Rittenhouse, H, Wei, JT, Groskopf, J, Chinnaiyan, AM (2011) Urine TMPRSS2:ERG fusion transcript stratifies prostate cancer risk in men with elevated serum PSA. Sci Transl Med 3: pp. 94ra72 26/scitranslmed.3001970" target="_blank" title="It opens in new window">CrossRef
  43. Grasso, CS, Wu, YM, Robinson, DR, Cao, X, Dhanasekaran, SM, Khan, AP, Quist, MJ, Jing, X, Lonigro, RJ, Brenner, JC, Asangani, IA, Ateeq, B, Chun, SY, Siddiqui, J, Sam, L, Anstett, M, Mehra, R, Prensner, JR, Palanisamy, N, Ryslik, GA, Vandin, F, Raphael, BJ, Kunju, LP, Rhodes, DR, Pienta, KJ, Chinnaiyan, AM, Tomlins, SA (2012) The mutational landscape of lethal castration-resistant prostate cancer. Nature 487: pp. 239-243 25" target="_blank" title="It opens in new window">CrossRef
  44. Fleischmann, A, Saramaki, OR, Zlobec, I, Rotzer, D, Genitsch, V, Seiler, R, Visakorpi, T, Thalmann, GN (2014) Prevalence and prognostic significance of TMPRSS2-ERG gene fusion in lymph node positive prostate cancers. Prostate 74: pp. 1647-1654 2/pros.22882" target="_blank" title="It opens in new window">CrossRef
  45. Nam, RK, Sugar, L, Wang, Z, Yang, W, Kitching, R, Klotz, LH, Venkateswaran, V, Narod, SA, Seth, A (2007) Expression of TMPRSS2:ERG gene fusion in prostate cancer cells is an important prognostic factor for cancer progression. Cancer Biol Ther 6: pp. 40-45 CrossRef
  46. Saramaki, OR, Harjula, AE, Martikainen, PM, Vessella, RL, Tammela, TL, Visakorpi, T (2008) TMPRSS2:ERG fusion identifies a subgroup of prostate cancers with a favorable prognosis. Clin Cancer Res 14: pp. 3395-3400 2.CCR-07-2051" target="_blank" title="It opens in new window">CrossRef
  
• 刊物主题：Human Genetics; Microarrays;
• 出版者：BioMed Central
• ISSN：1755-8794

文摘

Background Tumorigenesis is characterised by changes in transcriptional control. Extensive transcript expression data have been acquired over the last decade and used to classify prostate cancers. Prostate cancer is, however, a heterogeneous multifocal cancer and this poses challenges in identifying robust transcript biomarkers. Methods In this study, we have undertaken a meta-analysis of publicly available transcriptomic data spanning datasets and technologies from the last decade and encompassing laser capture microdissected and macrodissected sample sets. Results We identified a 33 gene signature that can discriminate between benign tissue controls and localised prostate cancers irrespective of detection platform or dissection status. These genes were significantly overexpressed in localised prostate cancer versus benign tissue in at least three datasets within the Oncomine Compendium of Expression Array Data. In addition, they were also overexpressed in a recent exon-array dataset as well a prostate cancer RNA-seq dataset generated as part of the The Cancer Genomics Atlas (TCGA) initiative. Biologically, glycosylation was the single enriched process associated with this 33 gene signature, encompassing four glycosylating enzymes. We went on to evaluate the performance of this signature against three individual markers of prostate cancer, v-ets avian erythroblastosis virus E26 oncogene homolog (ERG) expression, prostate specific antigen (PSA) expression and androgen receptor (AR) expression in an additional independent dataset. Our signature had greater discriminatory power than these markers both for localised cancer and metastatic disease relative to benign tissue, or in the case of metastasis, also localised prostate cancer. Conclusion In conclusion, robust transcript biomarkers are present within datasets assembled over many years and cohorts and our study provides both examples and a strategy for refining and comparing datasets to obtain additional markers as more data are generated.